Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease

Author： Chan Phylinda   Nutt John   Holford Nicholas  

Publisher： Springer Publishing Company

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.32, Iss.3-4, 2005-08, pp. : 307-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

By Fulvio Bracco  

CNS Drugs, Vol. 18, Iss. 11, 2004-01 ,pp. : 733-746

Adis International

Access to resources Recommend Favorite

The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease

By  

Current Clinical Pharmacology, Vol. 2, Iss. 3, 2007-01 ,pp. : 234-243

Bentham Science Publishers

Access to resources Recommend Favorite

Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease

By Lees Andrew  

Drugs & Aging, Vol. 22, Iss. 9, 2005-01 ,pp. : 731-740

Adis International

Access to resources Recommend Favorite

Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease: Strategies for Management

By van Laar T.  

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

By Stocchi Fabrizio  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1399-1407

Informa Healthcare

Access to resources Recommend Favorite